SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to a combination of factors, including recent earnings and a low float, leading to speculation about a potential short squeeze. The community is actively discussing price levels, profit-taking strategies, and the stock's potential for significant upward movement. Some traders are wary of the stock's history and caution against chasing gains.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $5 million production order and a $150 million registered direct offering, signaling strong institutional investor confidence. The community is actively discussing the implications of these developments for POET's growth in the AI infrastructure market and its potential to scale production. Discussions include comparing POET to other companies and analyzing the significance of partnerships with major industry players in photonics.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, potential rate cuts, and possible S&P 500 inclusion. The community is bullish, fueled by optimism around growth prospects, crypto offerings, and increasing membership. Many see a breakout above the $30 resistance level and are discussing potential price movements post-earnings.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors discuss the potential acquisition of Larvotto Resources and the implications of a rejected initial offer, alongside the company's existing DLA contract. Community members are debating the deal's valuation and potential government involvement, while emphasizing UAMY's position as a key domestic antimony producer amid global supply chain concerns and China's export policies. There is also growing anticipation for upcoming earnings announcements and speculation about new deals with Australia and NATO.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending after successful flight testing of its Black Widow drone using Palantir's visual navigation software in GPS-denied conditions, marking a potential breakthrough for military applications. The community is actively discussing the implications of this advancement and possible contract opportunities. Some investors express excitement and long-term bullish sentiment, while others are wary of short-term volatility and are actively trading the stock.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following news of a potential acquisition by Novartis, with the deal speculated to strengthen Novartis's neuroscience pipeline. The community is buzzing about the potential buyout price, the value of the spin-off company, and the implications for the broader RNA therapeutics sector. Some traders point to options activity as a signal and congratulate long-term holders.

YPF SA engages in the exploration, production, and distribution of oil and gas. It operates through the following segments: Upstream, Gas and Power, Downstream, Central Administration and Other. The Upstream segment sells petroleum and natural gas. The Gas and Power segment markets natural gas to third parties and downstream segment; and manages commercial and technical LNG Regasification Terminals in Bahia Blanca and Escobar. The Downstream segment produces petroleum refining and petrochemicals. The Central Administration and Other segment covers corporate administrative expenses and assets, construction activities, and the environmental remediation. The company was founded on June 2, 1977 and is headquartered in Buenos Aires, Argentina.

YPF - ADR

YPF S.A.

YPF is trending due to a rally in Argentina-focused equities, sparked by Javier Milei's election victory; the community is discussing the potential impacts of his policies, including privatization and dollarization, on YPF and the broader Argentine market, while also considering technical factors and unusual options activity.

Banco BBVA Argentina SA engages in the provision of banking and financial services. It operates through the following business lines: retail banking; small and medium-sized companies; and corporate and investment banking (CIB). The retail banking business includes checking and savings accounts, time deposits, credit cards, personal and auto loans, mortgages, insurance, and investment products. The small and medium-sized companies business focuses on local private-sector companies. The CIB business covers global transaction services and global markets solutions such as risk management and securities brokerage, long term financing products as well as project finance and syndicated loans, and corporate finance services. The company was founded on October 14, 1886 and is headquartered in Buenos Aires, Argentina.

BBVA Argentina - ADR

Banco Bbva Argentina SA

BBAR is trending as investors monitor Argentinian equities following recent political developments, with some anticipating a potential rally due to a shift in leadership. Community members are actively discussing the stock's potential for significant gains, while acknowledging the inherent volatility and risks associated with the Argentinian market. The stock's low P/E ratio and the potential for increased foreign investment are also key discussion points.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential acquisition by INCY and compare it to competitor KURA, particularly focusing on the safety profiles of their respective leukemia treatments. Community members are weighing the impact of a recent FDA approval for Syndax's Revuforj against concerns over a "black box" warning, while also evaluating future revenue potential and possible buyout scenarios.

Global X Funds - Global X MSCI Argentina ETF

The Argentina ETF, ARGT, is trending due to optimism surrounding Argentina's economic direction, particularly following recent political developments and government actions. Community discussions revolve around the potential impact of these changes and the fund's future performance, with some noting the country's ongoing economic challenges. Investors are closely watching how new policies will affect the fund's holdings and the broader Argentinian market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2025

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?

Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Matches Q2 Earnings Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and +1.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences drew heightened retail investor chatter on Wednesday after the FDA awarded Rare Pediatric Disease designation to its gene editing therapy PBGENE-DMD, which targets duchenne muscular dystrophy (DMD) treatment.The stock surged as much as 9% during regular trading but reversed course to close down 7.2% at $4.24, and extended losses in after-hours trading, slipping 3.5%.The designation, which is intended to provide incentives for the development of drugs and biologics for serious and life-threatening conditions that predominantly affect individuals under age 18, could provide Precision with a priority review voucher (PRV) upon approval of the drug.PRVs can be redeemed for accelerated FDA review of a different drug or sold to other companies, creating potential for non-dilutive capital.Precision’s chief development and business officer, Cindy Atwell, said the designation supports the potential of PBGENE-DMD to deliver a “meaningful improvement and durable functional benefit” for up to 60% of patients.PBGENE-DMD is a first-in-class in vivo gene editing therapy that uses the company’s proprietary Arcus platform, designed to excise exons 45–55 of the dystrophin gene using two Arcus nucleases delivered in a single Adeno-associated virus (AAV).&nbsp;The one-time treatment aims to restore a near full-length, naturally produced dystrophin protein, considered functional in humans.In preclinical studies, PBGENE-DMD showed:<ul class="todo-list"><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Significant, durable functional improvements in a humanized DMD mouse model</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Restoration of dystrophin production in key muscle types, including cardiac and skeletal muscle</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Editing of satellite muscle stem cells, believed to be important for long-term durability</label></li></ul>&nbsp;The company is currently completing final IND-enabling toxicology studies and said it expects to begin clinical testing in 2026.Precision also said that its Arcus platform enables precise, defined therapeutic gene edits using a small, structurally distinct nuclease, supporting gene insertion, elimination, and excision.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,025% surge in 24-hour message volume.One user pointed to Precision’s cash reserves of over $80 million and described the current setup as a “good risk-reward,” suggesting the downside appears limited while the potential upside could be unlimited.<stembedurl>https://stocktwits.com/pinkal/message/619015289</stembedurl>Another user, reflecting on a much higher cost basis from early 2021, assessed whether the current dip might offer a fresh buying opportunity.<stembedurl>https://stocktwits.com/foxhedgehog/message/618993420</stembedurl>The stock has declined 9.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

The FDA designation could make Precision eligible for a valuable Priority Review Voucher, while preclinical data showed strong dystrophin restoration across key muscle groups.

Equity

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Precision Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.34	--	--	N/A
Q2 '25	-$1.50	-$2.13	-42.00%	MISSED
Q1 '25	-$1.96	-$2.21	-12.85%	MISSED
Q4 '24	-$2.10	-$2.22	-5.55%	MISSED
Q3 '24	-$2.14	-$2.25	-5.34%	MISSED

DTIL
Precision Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest DTIL News

DTILPrecision Biosciences Inc